Louise Chen
Stock Analyst at Scotiabank
(3.19)
# 1,059
Out of 4,915 analysts
299
Total ratings
46.13%
Success rate
1.19%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $16.75 | +377.61% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.53 | +488.24% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $14.23 | -1.58% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.50 | +700.00% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $18.42 | +198.59% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $50.94 | +7.97% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.88 | +286.60% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $37.44 | +33.55% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $4.34 | +245.62% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $11.53 | +47.44% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $36.88 | +89.80% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $9.91 | +404.54% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $17.88 | +67.79% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $38.57 | +42.60% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.18 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $50.03 | +219.81% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $34.82 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $23.81 | +89.00% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $167.26 | +28.54% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.99 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $81.75 | +89.60% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.40 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $760.08 | +16.44% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.96 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.62 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.61 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.97 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.79 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $189.31 | +5.65% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.87 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.41 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.97 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.10 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $554.58 | +66.79% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.70 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.14 | +1,970.06% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.10 | +138.10% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $2.03 | +1,131.53% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $18.31 | +173.07% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.58 | +242.94% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.13 | +342.48% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.40 | +2,160.74% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.14 | +78,855,040.19% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $409.16 | -36.94% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $16.83 | -10.87% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.79 | +2,693.30% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.34 | +1,392.54% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.59 | +492.89% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $16.75
Upside: +377.61%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.53
Upside: +488.24%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $14.23
Upside: -1.58%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.50
Upside: +700.00%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.42
Upside: +198.59%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $50.94
Upside: +7.97%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.88
Upside: +286.60%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $37.44
Upside: +33.55%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.34
Upside: +245.62%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $11.53
Upside: +47.44%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $36.88
Upside: +89.80%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $9.91
Upside: +404.54%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $17.88
Upside: +67.79%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $38.57
Upside: +42.60%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.18
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $50.03
Upside: +219.81%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $34.82
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $23.81
Upside: +89.00%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $167.26
Upside: +28.54%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.99
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $81.75
Upside: +89.60%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.40
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $760.08
Upside: +16.44%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.96
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.62
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.61
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.97
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.79
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $189.31
Upside: +5.65%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.87
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.41
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.97
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.10
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $554.58
Upside: +66.79%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.70
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.14
Upside: +1,970.06%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.10
Upside: +138.10%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $2.03
Upside: +1,131.53%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $18.31
Upside: +173.07%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.58
Upside: +242.94%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.13
Upside: +342.48%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.40
Upside: +2,160.74%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.14
Upside: +78,855,040.19%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $409.16
Upside: -36.94%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $16.83
Upside: -10.87%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.79
Upside: +2,693.30%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.34
Upside: +1,392.54%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.59
Upside: +492.89%